Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065516 | 0.88 | GPR119 (0.44) | RBP4GPR119PDE10ACKS1BSKP1 | |
| SCHEMBL2065518 | 0.88 | GPR119 (0.44) | RBP4GPR119PDE10ACKS1BSKP1 | |
| SCHEMBL2065083 | 0.84 | GPR119 (0.46) | GPR119PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL2065084 | 0.84 | GPR119 (0.46) | GPR119PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL2065047 | 0.82 | LMNA (0.48) | PDE10A | |
| SCHEMBL2065048 | 0.82 | LMNA (0.48) | PDE10A | |
| SCHEMBL2064240 | 0.81 | SCN10A (0.43) | GPR119PDE10A | |
| SCHEMBL2064720 | 0.81 | NR3C1 (0.46) | GPR119PDE10A | |
| SCHEMBL2064718 | 0.81 | NR3C1 (0.46) | GPR119PDE10A | |
| SCHEMBL2064242 | 0.81 | SCN10A (0.43) | GPR119PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8648084-B2 | Selective substituted pyrazine ligands for neuronal nicotinic receptors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8148408-B2 | Selective substituted pyridine ligands for neuronal nicotinic receptors | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | RBP4 846/4885GPR119 76/4885PDE10A 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.